Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals director J. Kevin Buchi reported routine equity compensation moves. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common shares at no cash cost, bringing his direct holdings to 75,077 shares.
On May 6, 2026, he also received a new grant of 19,824 restricted stock units, each representing a contingent right to one Class A share. A separate trust associated with him holds 262,072 Class A shares indirectly. The filing shows no open-market stock purchases or sales.
Amneal Pharmaceuticals director Deborah M. Autor increased her equity stake through equity compensation activity. On May 7, 2026, 34,819 restricted stock units were converted into 34,819 shares of Class A Common Stock, reflecting an exercise of derivative securities. Following this settlement, she directly held 128,479 Class A shares. On May 6, 2026, she was also credited with 19,824 new restricted stock units, each representing a contingent right to receive one share of Class A Common Stock, adding to her unvested equity awards.
Amneal Pharmaceuticals director Jeffrey P. George reported routine equity compensation activity. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares and bringing his direct holdings to 344,614 shares.
These 34,819 restricted stock units were previously granted and each unit represented a right to receive one share of Class A Common Stock upon vesting. On May 6, 2026, he was also awarded 19,824 new restricted stock units, which will convert into Class A shares when they vest under the company’s standard vesting schedule tied to the annual meeting and one‑year anniversary of grant.
Amneal Pharmaceuticals director Gautam Patel increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units into the same number of shares of Class A Common Stock at a stated price of $0.00 per share. After this exercise, he directly owned 1,643,963 shares of Class A Common Stock. On May 6, 2026, he was also granted 19,824 restricted stock units, each representing a contingent right to receive one share of Class A Common Stock, which vest under the company’s director vesting schedule linked to the first annual meeting and one-year anniversary of grant.
Amneal Pharmaceuticals director John Kiely reported compensation-related equity activity. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares at a stated price of $0.00 per share. The Form 4 also shows a grant of 19,824 restricted stock units on May 6, 2026, each representing a right to receive one share of Class A Common Stock. After these transactions, Kiely directly owns 260,252 Class A Common Stock shares, with no remaining restricted stock units reported in this filing.
Amneal Pharmaceuticals director Ted C. Nark increased his equity stake through stock-based compensation. On May 7, 2026, he exercised 34,819 restricted stock units, receiving the same number of Class A Common Stock shares at a price of $0 per share, bringing his direct holdings to 325,848 shares.
The exercised units were part of a 34,819-unit award granted on May 6, 2025 that vested on May 7, 2026. On May 6, 2026, he also received a new grant of 19,824 restricted stock units, each representing a contingent right to one share of Class A Common Stock, with vesting tied to the company’s director vesting schedule.
Amneal Pharmaceuticals director Paul M. Meister reported equity compensation moves involving the company’s Class A Common Stock. On May 7, 2026, he exercised 48,747 Restricted Stock Units, receiving the same number of Class A shares, bringing his direct holdings to 832,800 shares.
Separately, on May 6, 2026, he received a new grant of 30,837 Restricted Stock Units, each representing a contingent right to one share of Class A Common Stock. A footnote states an earlier grant of 48,747 RSUs on May 6, 2025 vested on May 7, 2026.
Amneal Pharmaceuticals director Yanai Shlomo increased his equity stake through stock-based compensation activity. He exercised 34,819 restricted stock units into the same number of shares of Class A Common Stock and did not sell any shares. Following this exercise, he directly owns 320,804 shares. In a separate transaction, he also received a grant of 19,824 new restricted stock units, each representing a contingent right to receive one share of Class A Common Stock.
Amneal Pharmaceuticals, Inc. reported stronger results for the quarter ended March 31, 2026. Net revenue rose to $722.5 million from $695.4 million, while net income jumped to $78.0 million from $24.6 million. EPS for Class A shareholders increased to $0.20 basic versus $0.04 a year earlier as gross margin expanded, helped by lower cost of goods and reduced amortization.
The Specialty segment drove much of the growth with higher sales of CREXONT, BREKIYA autoinjector and UNITHROID, while Affordable Medicines also improved and AvKARE declined modestly. Amneal remains highly leveraged with $2.69 billion of term loans and senior notes and a stockholders’ deficiency of $46.0 million.
Cash, cash equivalents and restricted cash fell to $204.4 million from $312.9 million, partly due to $38.8 million of tax receivable agreement payments and initial opioid settlement installments. The company finalized its Nationwide Opioids Settlement Agreement and recorded approximately $79.3 million in related liabilities. After quarter-end, Amneal agreed to acquire Kashiv BioSciences for $375 million in cash, 28.9 million Class A shares and up to $350 million in contingent payments, and signed a major mirabegron supply and distribution deal with MSN Laboratories.
Amneal Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on May 6, 2026. Stockholders elected all 11 director nominees, including Deb Autor, Chintu Patel, Chirag Patel and Gautam Patel, to serve until the 2027 annual meeting and until their successors are elected and qualified.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. In addition, they ratified the selection of Ernst & Young LLP as Amneal’s independent registered public accounting firm for the fiscal year ending December 31, 2026.